Pirfenidon Accord 267 mg filmom obložene tablete Horvaatia - horvaadi - HALMED (Agencija za lijekove i medicinske proizvode)

pirfenidon accord 267 mg filmom obložene tablete

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - pirfenidon - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 267 mg pirfenidona

Pirfenidon Accord 801 mg filmom obložene tablete Horvaatia - horvaadi - HALMED (Agencija za lijekove i medicinske proizvode)

pirfenidon accord 801 mg filmom obložene tablete

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - pirfenidon - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 801 mg pirfenidona

Sorafenib Accord Euroopa Liit - horvaadi - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Plerixafor Accord Euroopa Liit - horvaadi - EMA (European Medicines Agency)

plerixafor accord

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Иммуностимуляторы, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Degarelix Accord Euroopa Liit - horvaadi - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prostatske neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Abiraterone Accord Euroopa Liit - horvaadi - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - abirateron acetat - prostatske neoplazme - endokrinska terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Fulvestrant Accord 250 mg otopina za injekciju u napunjenoj štrcaljki Horvaatia - horvaadi - HALMED (Agencija za lijekove i medicinske proizvode)

fulvestrant accord 250 mg otopina za injekciju u napunjenoj štrcaljki

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - fulvestrant - otopina za injekciju u napunjenoj štrcaljki - 250 mg - urbroj: jedna napunjena štrcaljka sadrži 250 mg fulvestranta u 5 ml otopine

Ciklofosfamid Accord 2000 mg prašak za otopinu za injekciju/infuziju Horvaatia - horvaadi - HALMED (Agencija za lijekove i medicinske proizvode)

ciklofosfamid accord 2000 mg prašak za otopinu za injekciju/infuziju

accord healthcare polska sp. z o.o., ul. lutomierska 50, pabianice, poljska - ciklofosfamid hidrat - prašak za otopinu za injekciju / infuziju - urbroj: 1 bočica 2000 mg ciklofosfamida u obliku ciklofosfamid hidrata, 1 ml rekonstituirane otopine sadrži 20 mg ciklofosfamida.

Daptomicin Accord Healthcare 350 mg prašak za otopinu za injekciju/infuziju Horvaatia - horvaadi - HALMED (Agencija za lijekove i medicinske proizvode)

daptomicin accord healthcare 350 mg prašak za otopinu za injekciju/infuziju

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - daptomicin - prašak za otopinu za injekciju / infuziju - urbroj: jedna bočica sadrži 350 mg daptomicina

Daptomicin Accord Healthcare 500 mg prašak za otopinu za injekciju/infuziju Horvaatia - horvaadi - HALMED (Agencija za lijekove i medicinske proizvode)

daptomicin accord healthcare 500 mg prašak za otopinu za injekciju/infuziju

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - daptomicin - prašak za otopinu za injekciju / infuziju - urbroj: jedna bočica sadrži 500 mg daptomicina